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SUMMARY (198 words) 
Background 
The pathogenesis of chronic pulmonary aspergillosis (CPA) including chronic 
necrotizing pulmonary aspergillosis (CNPA), chronic cavitary pulmonary aspergillosis 
(CCPA), and simple aspergilloma (SA) has been poorly investigated. We examined all 
types of CPA cases with histopathological evidence to clarify the differences in 
pathogenesis and clinical features. 
Method 
We searched for cases diagnosed as pulmonary aspergillosis by histopathological 
examination in Nagasaki University Hospital between 1964 and September 2010. All 
available clinical information including radiological findings were collected and 
analyzed. 
Result 
We found 7, 5, 8, and 7 cases of proven CNPA, probable CNPA, CCPA, and SA, 
respectively. The radiograph of proven and probable CNPA was initially infiltrates or 
nodules that progress to form cavities with or without aspergilloma, whereas the 
radiograph of CCPA showed pre-existed cavities and peri-cavitary infiltrates with or 
without aspergilloma. The patients with proven and probable CNPA exhibited not only 
respiratory symptoms but also systemic symptoms and malnutrition. Aspergillus 
fumigatus was the most frequently isolated Aspergillus species (n = 14), however, A. 
niger was the predominant isolated species in proven CNPA cases (n = 4).   
Conclusion 
Our data indicate that the cases with chronic infiltration, progressive cavitation, and 
subsequent aspergilloma formation should be diagnosed as CNPA, and the cases with 
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pre-existed cavities showing peri-cavitary infiltrates with or without aspergilloma would 
mean CCPA. However, it may be difficult to distinguish the two subtypes if a series of 
adequate radiography films are not available. We propose the term “chronic progressive 





Chronic pulmonary aspergillosis (CPA) was originally established in the early 1980s 
by Binder as chronic necrotizing pulmonary aspergillosis (CNPA) [1] and semi-invasive 
aspergillosis (SIA) by Gefter [2]. CNPA/SIA is characterized by a slow progressive 
cavitating process in the lungs due to Aspergillus spp. infection. In the last decade, new 
clinical nomenclature and definition of chronic forms of aspergillosis have been 
proposed [3-5], and recent guidelines from the Infectious Diseases Society of America 
(IDSA) have indicated 3 major subtypes of chronic forms of pulmonary aspergillosis, 
namely CNPA (categorized in subacute invasive form of aspergillosis; subacute IPA), 
chronic cavitary pulmonary aspergillosis (CCPA), and aspergilloma [6]. Aspergilloma 
was traditionally classified as simple or complex in the surgical literature, and complex 
aspergilloma is considered CCPA by current IDSA guidelines [6, 7]. Updated IDSA 
guidelines and textbook have indicated that the differences between CNPA and CCPA 
include prolonged time frame (CNPA, 1–3 months vs. CCPA, >3 months) [8]. The 
original CNPA cases defined by Binder are not equal to those of CNPA cases defined by 
Denning. Establishing the precise sub-classifications of CPA, while challenging, is 
important for clinical trials as well as the development of tools for its diagnosis and 
treatment. The pathogenesis of each type of CPA examined by pathological samples has 
been poorly investigated. In this study, we investigated all types of CPA cases including 
CNPA, CCPA, and simple aspergilloma (SA) diagnosed by histopathological 
examination to clarify the differences in the pathogenesis and clinical features of each 
type of CPA. In particular, revealing the difference between CNPA and CCPA is the 
most important of goal of our study. This study was performed in a single medical 
teaching hospital in Japan. 
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MATERIAL AND METHODS 
Case collection and analysis 
We searched for cases diagnosed as “pulmonary aspergillosis” by histopathological 
examination of respiratory specimens acquired by biopsy, surgical resection, or autopsy 
in Nagasaki University Hospital. Nagasaki University Hospital is a Japanese teaching 
hospital that contains 860 beds and is located in the southwestern part of Japan. All 
cases registered in the database between 1964 and September 2010 were screened, and 
patient data such as sex, age, underlying diseases, clinical symptoms, clinical course, 
laboratory and radiological findings, and treatment was collected from medical records 
and analyzed. This retrospective study was approved by the ethics committee of 
Nagasaki University Hospital. 
 
Definition of pulmonary aspergillosis subtypes by histopathological and clinical 
aspects 
The histopathological and clinical definition of invasive pulmonary aspergillosis 
(IPA), CNPA, CCPA, and SA in this study is indicated in Figure 1. A diagnosis of IPA 
and CNPA requires extensive hyphal invasion in the lung parenchyma and localized 
hyphal invasion in cavity walls and/or destroyed lung tissue, respectively. Non-invasive 
CPA was subdivided into three groups as Group A, CCPA and SA. CCPA requires pre-
existing cavities and disease progression within 3 months. SA requires a solitary 
cavitary legion with an aspergilloma and no disease progression within 3 months. Group 
A does not match to either of CNPA and CCPA. This group requires a newly developed 
necrotic lung cavity and no hyphal invasion in any lung tissue. The existence of pre-





The chi-square test was used for qualitative variables. Multivariate logistic 
regression analysis was performed using the variables that were selected from univariate 
analysis (P < 0.1). This analysis was performed by SPSS ver. 16 software. P values 






Characters of CPA cases and patients 
A total of 60 cases of which histopathological findings indicated pulmonary 
aspergillosis were found in the database. Then the cases of IPA and allergic 
bronchopulmonary aspergillosis (ABPA) were excluded. We searched the patients’ 
medical records including X-ray films and accepted 27 cases of CPA for further analysis 
due to their availability of medical information and X-ray films. We found 7, 5, 8, and 7 
cases of CNPA, Group A, CCPA, and SA, respectively. They were histopathologically 
diagnosed by surgical resection in 19, biopsy in 4, and autopsy in 4 cases, respectively. 
Table 1 shows sex, age, body mass index, symptoms, and disease duration prior to 
diagnosis. The cases of CNPA, Group A and CCPA demonstrated a male predominance, 
and the body mass index values of patients with CNPA and Group A were statistically 
lower than those of patients with SA. Several patients with SA complained of cough, 
hemoptysis, and sputum; however, the symptoms or radiographic findings did not 
indicate disease progression within 3 months. All cases with CNPA, Group A and CCPA 
complained respiratory symptoms. Progressive fever and weight loss were found in only 
CNPA and Group A cases, which may reflect progressive tissue destruction and more 
direct inflammatory responses than CCPA and SA does.  
The underlying conditions of patients with CPA are indicated in Table 2. Patients 
with CNPA most frequently had chronic obstructive pulmonary disease (COPD) or 
emphysema, whereas patients with CCPA and SA most frequently had prior 
tuberculosis. A history of pneumonia was detected in 3/7 and 4/5 cases of CNPA and 
Group A, respectively, and may have been caused by a direct or indirect response to 
Aspergillus spp. A history of thoracic surgery or pneumothorax was also detected in 
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CNPA and Group A cases. Diabetes mellitus was the predominant underlying systemic 
disease in all subtypes of CPA cases. Cigarette smoking was also seen in all subtypes of 
CPA cases. Malnutrition was seen in 4/7, 4/5 and 3/8 cases of Group A, CNPA and 
CCPA, respectively. 
 
Radiological findings of patients with CPA 
Typical radiographic images of each subtypes of CPA are presented in Figure 2. 
The radiograph of CNPA and Group A cases was initially infiltrates that progress to 
form cavities with or without aspergilloma. The radiograph of CCPA cases showed pre-
existed cavities and peri-cavitary infiltrates with or without aspergilloma, and SA cases 
showed a single cavity with aspergilloma. Radiological findings at the time of diagnosis 
are summarized in Table 3. The upper lobes were affected in all cases of CPA, while 
both the right and left upper lobes were affected in 4/7 and 1/5 cases of CNPA and 
Group A, respectively. Although the upper lobes were most commonly affected, the 
middle and the lower lobes were also affected in CCPA and SA cases. Cavitary 
infiltrates with aspergilloma was the predominant finding in CNPA and Group A cases. 
Cavitary nodules with aspergilloma were also recognized in CNPA cases. Cavities with 
aspergilloma were most commonly found in CCPA cases. All SA cases showed a single 
cavity with aspergilloma. Aspergillomas were recognized in 4/7, 5/5, 6/8, and 7/7 cases 
of CNPA, Group A, CCPA, and SA, respectively.   
 
Laboratory findings of patients with CPA 
Laboratory findings are presented in Table 4. Aspergillus spp. were isolated in 6/7 
(86%), 4/5 (80%), 7/8 (88%), and 4/7 (57%) from CNPA, Group A, CCPA, and SA 
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cases, respectively. A. fumigatus was the most frequently isolated Aspergillus species (n 
= 14), followed by A. niger (n = 5), A. flavus (n = 2), and A. terreus (n = 1) in all CPA 
cases; while A. niger was the predominant isolated species in CNPA cases (n = 4). Anti-
Aspergillus antibody tests were positive in 3/5 (60%), 3/4 (75%), 4/8 (50%), and 1/6 
(17%) cases of CNPA, Group A, CCPA, and SA, respectively. Aspergillus antigen tests 
were positive in 5/6 (83%), 4/5 (80%) and 6/6 (100%) cases of CNPA, Group A and 
CCPA, respectively. However, it was negative in all SA cases. A few CPA cases had a 
positive β-D-glucan test. The inflammatory marker results indicated a lower positive 
rate of leukocytosis compared to C-reactive protein and erythrocyte sedimentation rate 
(ESR), although the number of cases in which ESR was measured was low. The number 
of cases in which any of the 3 inflammatory markers tested positive was 5/7 (71%), 5/5 
(100%), 4/8 (50%), and 2/7 (29%) in CNPA, Group A, CCPA, and SA, respectively. 
 
DISCUSSION 
The pathogenesis of CPA, especially CNPA and CCPA, has not been widely 
investigated, and the noncommittal definition criteria and overlapping clinical features 
make it difficult to distinguish the two subtypes. The clinical time course, radiological 
findings, and defects in innate immunity may be indexes of differences as suggested by 
Denning and others [3, 5, 6, 8, 9], however, sub-classification of CPA should be made 
according to the pathogenesis of the disease on the basis of pathological and 
radiological features. Although this study is retrospective, we collected a total of 27 
CPA cases with complete pathological, radiological, microbiological, and serological 
findings.  
The clinical distinction between SA and other CPA subtypes may not be difficult 
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because of it presents with obvious radiological findings and clinical features. All 7 SA 
cases in our series showed a solitary cavity with an aspergilloma. On the other hand, 
discerning the difference between CNPA and CCPA is challenging. Binder et al. 
described that CNPA is defined as an indolent, cavitating process in the lungs due to the 
invasion of lung tissue by a fungus of the Aspergillus spp.. Gefter et al. reported that the 
radiographic features of SIA include chronic infiltration, progressive cavitation, and 
subsequent mycetoma formation, and that the absence of a previous cavity distinguishes 
such cases from secondary noninvasive mycetomas. While, Denning et al. defined 
CNPA as subacute invasive form of aspergillosis, occurring over 1–3 month, and CCPA 
as non-invasive chronic cavitary aspergillosis, occurring >3 months. According to 
Denning et al., the development of CCPA lesions involves two possible ways of cavity 
formation: 1) the infiltrates were initially ill-defined areas of consolidation that 
progressed to form well-defined cavit 
es; and 2) the cavities were pre-existing (i.e., in cases of previous tuberculosis or 
bronchiectasis) [4]. However, the former radiographic features are concordant with 
those of Binder’s CNPA or Gefter’s SIA. Thus, the consensus of definition of CNPA is 
not established, and some cases of Denning’s CCPA may be Binder’s CNPA.  
In this study, we defined the cases with progressive cavitating processes in the lung 
without a pre-existing cavity and presence of hyphal invasion into lung parenchyma as 
CNPA, and the cases with pre-existing cavities and peri-cavitary infiltrates and presence 
of hyphae in a cavity but not in lung parenchyma as CCPA. However, whether group A 
in our series is classified into CNPA or CCPA is controversial. The radiographic features 
of CNPA and Group A cases are similar; they are chronic infiltration, progressive 
cavitation and subsequent aspergilloma formation. The pathological features of the 
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cavity wall of CNPA and Group A cases are similar except hyphal invasion; they are 
acute and chronic inflammation, granulation, parenchymal necrosis and subsequent 
cavity formation with or without fragments of destroyed lung tissue in the cavity. The 
hyphal invasion into cavity wall was observed only in CNPA cases but not Group A 
cases. Antifungals treatment before the pathological examinations were conducted in 
3/7 and 4/5 cases of CNPA and Group A, respectively. Additionally, duration of 
treatment was relatively longer in Group A cases (6 weeks to 8 months) compared to 
that of CNPA(10 days for two case) except one case (approximately 14 months). It is 
possible that antifungal treatment prior to the pathological examination may block the 
hyphal invasion of Aspergillus in Group A cases. Moreover, systemic symptoms such as 
fever and weight loss, and underlying conditions such as history of pneumonia or 
thoracic surgery are common to both CNPA and Group A, but not to CCPA. Thus, the 
pathological and clinical features and backgrounds of Group A cases were resemble to 
those of CNPA cases; which means the pathogenesis of CNPA and Group A cases is 
considered the same.  
It is supposed that Aspergillus infects air spaces, such as emphysematous bullae, 
then destroys lung tissue by invasion and/or mycotic toxins, proteolytic enzymes, and 
metabolites produced by Aspergillus. Proteolytic enzymes and oxidant derived from 
neutrophils and macrophages may also cause tissue necrosis. Thus, the cavity formation 
can be developed even though the hyphal invasion is minimal or absent. Therefore, the 
cases with chronic infiltration, progressive cavitation, and subsequent aspergilloma 
formation should be diagnosed as CNPA; the cases in which hyphal invasion of lung 
tissue is demonstrated are proven CNPA and the cases in which the invasion is not 
demonstrated are probable CNPA. Hence, we diagnose the Group A in our series as 
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probable CNPA. The median duration of the disease was 3 and 24 months in proven 
CNPA and probable CNPA (Group A) cases, respectively. As Binder et al. mentioned 
that the disease is usually of 1 to 6 months duration but can be present for years prior to 
diagnosis, CNPA is not always subacute (1–3 months). 
There were pre-existing cavities such as sequelae of pulmonary tuberculosis, 
bronchiectasis, COPD, bullae, and interstitial pneumonia in all 8 of CCPA cases, and the 
wall of these cases was composed of chronic inflammatory, granulation, and fibrous 
tissue layers, and the inner surface of the cavity is covered by bronchial epithelium or 
metaplastic squamous cell epithelium in part. Thus, CCPA is synonymous with complex 
aspergilloma. Our study results indicate that CNPA can be distinguishable from CCPA 
by careful observation of progression of the cavitary lesion if a series of adequate 
radiography films are available. In some cases, however, it will be difficult to 
distinguish the two subtypes because adequate films are not always available.   
The limitations of our study include its retrospective nature, the number of cases 
being insufficient for establishing definite criteria, and the need for additional 
information. The importance of differentiating between CNPA and CCPA is scientific; 
however, it may be difficult because of the noncommittal definition criteria and 
existence of overlapping findings. From the management perspective, its elucidation 
does not provide deeper insight into the differentiation, except for executing clinical 
trials. Although we respect and follow the original definition of CNPA and the concept 
of CCPA, there is a limitation to distinguishing these two entities in actual clinical 
settings as discussed above. Hope et al. indicated that apparent distinct entities do not 
exist for the CPA subtypes and that these forms usually overlap; therefore, the 
requirement and importance of the rigorous sub-classifications of CPA are unclear [5]. 
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Hence, we propose the term “chronic progressive pulmonary aspergillosis (CPPA)” for 
the clinical syndrome including both CNPA and CCPA [10]. Therefore, CPA is consisted 
of CPPA and SA. 
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Figure 1. Histopathological and clinical diagnosis of pulmonary aspergillosis in this 
study. 
A diagnosis of invasive pulmonary aspergillosis and chronic necrotizing pulmonary 
aspergillosis (CNPA) requires extensive hyphal invasion in the lung parenchyma and 
localized hyphal invasion in cavity walls and/or destroyed lung tissue, respectively. 
Group A, chronic cavitary pulmonary aspergillosis (CCPA), and simple aspergilloma 
(SA) require no hyphal invasion in any lung tissue; however, Group A requires new 
cavity formation and clinical deterioration without a pre-existing cavitary lesion in the 
lung. CCPA requires pre-existing cavities and disease progression and SA requires a 
solitary cavitary legion with an aspergilloma and no clinical deterioration within 3 
months.  
 
Figure 2. Chest radiographic images of CPA cases  
A) CNPA: the patient (75-year-old man) had chronic obstructive lung disease and a 
history of left pneumonectomy for intractable pulmonary tuberculosis and aspergilloma 
7 years before admission. The radiographs show consolidation around bullae and pleural 
thickening in the right upper lung. B) Group A: the patient (75-year-old man) had 
diabetes mellitus and a history of pneumonia 2 years before admission. The radiographs 
show consolidation around cavities with aspergilloma and pleural thickening in the right 
upper lung. C) CCPA: the patient (69-year-old man) had a history of pulmonary 
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tuberculosis. The radiographs show multiple cavities with aspergilloma in the right 
upper lung. D) Simple aspergilloma: the patient (40-year-old man) had a history of 
bullectomy for left pneumothorax 6 years before admission. The radiographs show a 













CNPA, chronic necrotizing pulmonary aspergillosis; CCPA, chronic cavitary pulmonary aspergillosis; SA, simple pulmonary aspergilloma; m, 
months; and y, years. 
*: statistical difference between CNPA, Group A and SA was indicated (p < 0.05)
 CNPA (n=7) Group A (n=5) CCPA (n=8) SA (n=7) 
Sex; Male/Female 6/1 4/1 7/1 3/4 
Age; mean (range) 59.1 (45–75) 67.0 (50–77) 69.7 (58–80) 56.6 (40–68) 
Body mass index; mean (range) 18.0* (13.0–21.4) 16.9* (13.9–18.8) 20.2 (15.7–25.7) 21.3 (18.0–23.9) 
Symptoms     
cough 5 5 7 4 
sputum 5 2 3 3 
hemoptysis 1 5 6 4 
dyspnea 3 1 2 0 
fever 4 2 0 0 
malaise 3 0 0 0 
weight loss 1 2 0 0 
Duration; median (range) 3M (1m–6y) 24M (17m–6y) 29M (6m–5y4m) 24M (6m–4y) 
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 CNPA (n=7) Group A (n=5) CCPA (n=8) SA (n=7) 
Respiratory conditions     
Prior tuberculosis 2 1 3 4 
Bronchiectasis 1 3 2 3 
Prior pneumonia 3 4 0 2 
Pneumothorax or bullae 1 3 2 2 
COPD or emphysema 5 0 1 0 
Prior thoracic surgery 2 2 1 1 
Others respiratory conditions* 2 4 9 4 
Systemic conditions     
 Diabetes Mellitus 3 2 2 2 
 Steroid usage 2 0 2 0 
 Other systemic conditions** 4 0 3 8 
 Smoking (>20y) 5 2 7 2 
 Malnutrition (BMI<18.5) 4 4 3 1 
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CNPA, chronic necrotizing pulmonary aspergillosis; CCPA, chronic cavitary pulmonary aspergillosis; SA, simple pulmonary aspergilloma; 
COPD, chronic obstructive pulmonary disease  
*: bronchial asthma (4 cases), lung cancer (4 cases), chronic parasinusitis (4 cases), prior pleuritis (2 cases), interstitial pneumonia (2 cases), 
eosinophilic pneumonia (1 case), non-tuberculous mycobacteriosis (1 case) and pneumoconiosis (1 case)  
**: gastric cancer (2 cases), colon cancer (1 case), prostate cancer (1 case), rheumatoid arthritis (1 case), Harada disease (1 case), ovarial cyst (2 
cases), nasal disease (3 cases), liver disease (1 case), alcoholism (2 cases), and acoustic neuroma (1 case).  
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Table 3. Radiological findings of CPA patients 
 
CNPA, chronic necrotizing pulmonary aspergillosis; CCPA, chronic cavitary pulmonary aspergillosis; SA, simple pulmonary aspergilloma. RUL, 
right upper lobe; LUL, left upper lobe; RML, right middle lobe; RLL, right lower lobe; LLL, left lower lobe.  
*; intrabronchial aspergilloma. 
 CNPA (n=7) Group A (n=5) CCPA (n=8) SA (n=7) 
Affected sites     
    RUL + LUL 4 1 0 0 
    RUL 3 3 3 2 
    RML 0 0 2 2 
    RLL 0 0 1 1 
    LUL 0 1 0 2 
    LLL 0 0 2 0 
  Cavities with aspergilloma 2 1 5 0 
  Cavity with aspergilloma 1 0 1 7 
  Cavities without aspergilloma 1 1 0 0 
  Cavitary infiltrates with aspergilloma 3 4 0 0 
  Cavitary infiltrates without aspergilloma 1 0 0 0 
  Cavitary nodules with aspergilloma 2 0 0 0 
 Multiple nodules 1 0 0 0 
  Bronchiectasis and infiltrate* 0 0 1 0 
  Bronchiectasis and atelectasis* 0 0 1 0 
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Table 4. Laboratory findings of CPA patients 
CNPA, chronic necrotizing pulmonary aspergillosis; CCPA, chronic cavitary pulmonary aspergillosis; SA, simple pulmonary aspergilloma; CRP, 
C-reactive protein; and ESR, Erythrocyte sedimentation rate.   
*: A. terreus was isolated with A. fumigatus from the same patient
 CNPA (n=7) Group A (n=5) CCPA (n=8) SA (n=7) 
Isolation of Aspergillus spp.     
    A. fumigatus 2 4 5 3 
    A. niger 4 0 1 0 
    A. flavus 0 0 1 1 
    A. terreus 1* 0 0 0 
    not identified 1 1 1 3 
Serological findings     
    Anti-aspergillus antibody (+) 3/5 3/4 4/8 1/6 
    Aspergillus antigen (≥ 0.5 C.O.I.) 5/6 4/5 6/6 0/5 
    β-D-glucan (≥ 20 pg/ml) 2/6 1/4 1/5 1/4 
Inflammatory makers     
    Leukocytosis (WBC>9000 /mm3) 2 0 1 0 
    CRP (>0.3 mg/dl) 5 4 4 0 
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Figure 2. Chest radiographic images of CPA cases 
